bluebird bio analyst ratings
bluebird bio analyst ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/05/2022 | -11.51% | Barclays | $3 → $5 | Upgrades | Underweight → Equal-Weight |
08/02/2022 | 41.59% | Raymond James | → $8 | Upgrades | Market Perform → Outperform |
05/24/2022 | -64.6% | Goldman Sachs | $3 → $2 | Maintains | Sell |
05/17/2022 | -46.9% | Morgan Stanley | $5 → $3 | Maintains | Underweight |
05/10/2022 | -46.9% | Barclays | $4 → $3 | Maintains | Underweight |
04/06/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
04/06/2022 | 41.59% | SVB Leerink | $10 → $8 | Maintains | Market Perform |
03/08/2022 | 41.59% | Wells Fargo | $12 → $8 | Maintains | Equal-Weight |
03/07/2022 | -11.51% | Morgan Stanley | $6 → $5 | Maintains | Underweight |
03/07/2022 | -29.21% | Barclays | $13 → $4 | Downgrades | Equal-Weight → Underweight |
03/07/2022 | 76.98% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
01/06/2022 | 76.98% | Morgan Stanley | $11 → $10 | Maintains | Underweight |
11/08/2021 | 76.98% | Goldman Sachs | $23 → $10 | Downgrades | Neutral → Sell |
11/08/2021 | 130.08% | Barclays | $20 → $13 | Maintains | Equal-Weight |
11/08/2021 | 94.68% | Morgan Stanley | → $11 | Downgrades | Equal-Weight → Underweight |
09/22/2021 | 307.07% | Mizuho | $29 → $23 | Maintains | Buy |
08/10/2021 | 253.97% | Canaccord Genuity | $86 → $20 | Downgrades | Buy → Hold |
08/10/2021 | 307.07% | Goldman Sachs | $63 → $23 | Downgrades | Buy → Neutral |
08/10/2021 | 342.46% | Wells Fargo | $60 → $25 | Downgrades | Overweight → Equal-Weight |
07/16/2021 | 519.45% | Morgan Stanley | $36 → $35 | Maintains | Equal-Weight |
07/01/2021 | 519.45% | Berenberg | → $35 | Downgrades | Buy → Hold |
04/19/2021 | 537.15% | Morgan Stanley | $45 → $36 | Maintains | Equal-Weight |
03/29/2021 | 1174.29% | SVB Leerink | $69 → $72 | Maintains | Outperform |
03/10/2021 | 1121.2% | Mizuho | $34 → $69 | Upgrades | Neutral → Buy |
03/02/2021 | 696.43% | Morgan Stanley | $50 → $45 | Maintains | Equal-Weight |
02/17/2021 | 590.24% | JP Morgan | $76 → $39 | Downgrades | Overweight → Neutral |
11/11/2020 | 1032.7% | Berenberg | → $64 | Initiates Coverage On | → Buy |
11/11/2020 | 784.92% | Morgan Stanley | $68 → $50 | Maintains | Equal-Weight |
11/05/2020 | 873.42% | Piper Sandler | $70 → $55 | Maintains | Neutral |
11/05/2020 | 1333.58% | B of A Securities | $100 → $81 | Maintains | Buy |
11/05/2020 | 1652.15% | SVB Leerink | $133 → $99 | Maintains | Outperform |
11/05/2020 | 891.12% | BMO Capital | → $56 | Downgrades | Outperform → Market Perform |
10/20/2020 | 2076.91% | Mizuho | → $123 | Initiates Coverage On | → Buy |
08/10/2020 | 1103.5% | Morgan Stanley | $73 → $68 | Maintains | Equal-Weight |
08/06/2020 | 1811.44% | BMO Capital | $112 → $108 | Maintains | Outperform |
08/06/2020 | 1333.58% | Wedbush | $89 → $81 | Maintains | Outperform |
07/13/2020 | 1669.85% | B of A Securities | $104 → $100 | Maintains | Buy |
06/12/2020 | 2253.9% | SVB Leerink | $129 → $133 | Maintains | Outperform |
05/28/2020 | 1191.99% | Morgan Stanley | $69 → $73 | Maintains | Equal-Weight |
05/28/2020 | 2183.11% | SVB Leerink | $125 → $129 | Maintains | Outperform |
05/13/2020 | 1669.85% | RBC Capital | → $100 | Initiates Coverage On | → Outperform |
05/12/2020 | 1882.23% | BMO Capital | $107 → $112 | Maintains | Outperform |
04/15/2020 | 1121.2% | Morgan Stanley | $92 → $69 | Maintains | Equal-Weight |
03/27/2020 | 1138.89% | Stifel | $94 → $70 | Upgrades | Hold → Buy |
02/26/2020 | 1528.26% | Morgan Stanley | $100 → $92 | Maintains | Equal-Weight |
02/19/2020 | 1563.66% | Stifel | $96 → $94 | Maintains | Hold |
02/03/2020 | 1669.85% | Evercore ISI Group | $86 → $100 | Upgrades | In-Line → Outperform |
12/13/2019 | 2289.3% | Oppenheimer | → $135 | Upgrades | Perform → Outperform |
12/09/2019 | 2731.76% | Wells Fargo | $242 → $160 | Maintains | Overweight |
11/26/2019 | 2006.12% | SVB Leerink | → $119 | Upgrades | Market Perform → Outperform |
11/19/2019 | 1422.07% | Evercore ISI Group | → $86 | Downgrades | Outperform → In-Line |
11/04/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
11/01/2019 | 1404.37% | Piper Sandler | $120 → $85 | Maintains | Neutral |
11/01/2019 | 1669.85% | Morgan Stanley | $104 → $100 | Maintains | Equal-Weight |
10/11/2019 | 1740.64% | Morgan Stanley | $136 → $104 | Maintains | Equal-Weight |
10/01/2019 | 1829.14% | Stifel | → $109 | Initiates Coverage On | → Hold |
08/12/2019 | — | William Blair | Downgrades | Outperform → Market Perform | |
08/06/2019 | 2306.99% | Morgan Stanley | $143 → $136 | Maintains | Equal-Weight |
06/18/2019 | 2731.76% | Maxim Group | → $160 | Upgrades | Hold → Buy |
06/17/2019 | 2784.85% | BMO Capital | $191 → $163 | Maintains | Outperform |
05/15/2019 | 2218.5% | Wedbush | $166 → $131 | Downgrades | Outperform → Neutral |
03/05/2019 | — | Leerink Swann | Downgrades | Outperform → Market Perform | |
02/26/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
01/23/2019 | 2749.46% | Canaccord Genuity | $250 → $161 | Maintains | Buy |
12/20/2018 | — | Raymond James | Initiates Coverage On | → Strong Buy | |
12/19/2018 | 2112.31% | Morgan Stanley | $185 → $125 | Maintains | Equal-Weight |
12/06/2018 | 2023.82% | Piper Sandler | $240 → $120 | Downgrades | Overweight → Neutral |
11/28/2018 | 2466.28% | Leerink Swann | → $145 | Initiates Coverage On | → Outperform |
11/05/2018 | 3174.22% | Morgan Stanley | $186 → $185 | Maintains | Equal-Weight |
11/05/2018 | 2837.95% | Wedbush | $204 → $166 | Maintains | Outperform |
11/05/2018 | 2908.74% | Janney Montgomery Scott | $170 → $170 | Upgrades | Neutral → Buy |
10/15/2018 | 3191.92% | Morgan Stanley | $190 → $186 | Maintains | Equal-Weight |
06/19/2018 | 3970.65% | Evercore ISI Group | $175 → $230 | Upgrades | In-Line → Outperform |
05/31/2018 | 4147.64% | Piper Sandler | → $240 | Assumes | Overweight → Overweight |
05/03/2018 | 3722.87% | BMO Capital | $222 → $216 | Maintains | Outperform |
03/21/2018 | 3598.98% | Morgan Stanley | $152 → $209 | Maintains | Equal-Weight |
03/14/2018 | 3793.67% | Janney Montgomery Scott | → $220 | Initiates Coverage On | → Neutral |
03/05/2018 | 4183.03% | William Blair | → $242 | Initiates Coverage On | → Outperform |
02/26/2018 | 2590.17% | Morgan Stanley | $151 → $152 | Maintains | Equal-Weight |
02/22/2018 | 3758.27% | B of A Securities | $185 → $218 | Maintains | Neutral |
02/22/2018 | 3829.06% | BMO Capital | $215 → $222 | Maintains | Outperform |
01/25/2018 | — | Leerink Swann | Downgrades | Outperform → Market Perform | |
12/21/2017 | — | Oppenheimer | Initiates Coverage On | → Perform | |
12/13/2017 | — | Maxim Group | Downgrades | Buy → Hold | |
12/11/2017 | — | Jefferies | Upgrades | Hold → Buy | |
12/05/2017 | 3475.09% | Canaccord Genuity | → $202 | Initiates Coverage On | → Buy |
11/30/2017 | 3439.7% | Maxim Group | $170 → $200 | Maintains | Buy |
11/06/2017 | — | Evercore ISI Group | Downgrades | Outperform → In-Line | |
11/03/2017 | 2784.85% | SunTrust Robinson Humphrey | $108 → $163 | Maintains | Buy |
11/03/2017 | — | Morgan Stanley | Upgrades | Underweight → Equal-Weight | |
11/02/2017 | 2767.16% | Barclays | $151 → $162 | Maintains | Overweight |
11/02/2017 | — | BTIG | Upgrades | Neutral → Buy | |
10/30/2017 | 2767.16% | BMO Capital | $134 → $162 | Maintains | Outperform |
10/16/2017 | — | Evercore ISI Group | Upgrades | In-Line → Outperform | |
10/11/2017 | — | Jefferies | Downgrades | Buy → Hold | |
10/02/2017 | — | Morgan Stanley | Downgrades | Equal-Weight → Underweight | |
09/07/2017 | 2572.47% | Barclays | → $151 | Initiates Coverage On | → Overweight |
08/17/2017 | 1705.25% | Evercore ISI Group | → $102 | Initiates Coverage On | → In-Line |
08/07/2017 | 1758.34% | Morgan Stanley | $103 → $105 | Maintains | Equal-Weight |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
08/05/2022 | -11.51% | 巴克莱 | $3 → $5 | 升级 | 重量不足的→等重 |
08/02/2022 | 41.59% | 雷蒙德·詹姆斯 | → $8 | 升级 | 市场表现优于→ |
05/24/2022 | -64.6% | 高盛 | $3 → $2 | 维护 | 卖 |
05/17/2022 | -46.9% | 摩根士丹利 | $5 → $3 | 维护 | 体重不足 |
05/10/2022 | -46.9% | 巴克莱 | $4 → $3 | 维护 | 体重不足 |
04/06/2022 | — | 考恩公司 | 评级下调 | 跑赢→市场表现 | |
04/06/2022 | 41.59% | SVB Leerink | $10 → $8 | 维护 | 市场表现 |
03/08/2022 | 41.59% | 富国银行 | $12 → $8 | 维护 | 等重 |
03/07/2022 | -11.51% | 摩根士丹利 | $6 → $5 | 维护 | 体重不足 |
03/07/2022 | -29.21% | 巴克莱 | $13 → $4 | 评级下调 | 等重→减码 |
03/07/2022 | 76.98% | SVB Leerink | $11 → $10 | 维护 | 市场表现 |
01/06/2022 | 76.98% | 摩根士丹利 | $11 → $10 | 维护 | 体重不足 |
11/08/2021 | 76.98% | 高盛 | $23 → $10 | 评级下调 | 中性→销售 |
11/08/2021 | 130.08% | 巴克莱 | $20 → $13 | 维护 | 等重 |
11/08/2021 | 94.68% | 摩根士丹利 | → $11 | 评级下调 | 等重→减码 |
09/22/2021 | 307.07% | 瑞穗 | $29 → $23 | 维护 | 买 |
08/10/2021 | 253.97% | 卡纳科特·格纳奇 | $86 → $20 | 评级下调 | 购买→Hold |
08/10/2021 | 307.07% | 高盛 | $63 → $23 | 评级下调 | 购买→中性 |
08/10/2021 | 342.46% | 富国银行 | $60 → $25 | 评级下调 | 超重→等重 |
07/16/2021 | 519.45% | 摩根士丹利 | $36 → $35 | 维护 | 等重 |
07/01/2021 | 519.45% | 贝伦伯格 | → $35 | 评级下调 | 购买→Hold |
04/19/2021 | 537.15% | 摩根士丹利 | $45 → $36 | 维护 | 等重 |
03/29/2021 | 1174.29% | SVB Leerink | $69 → $72 | 维护 | 跑赢大盘 |
03/10/2021 | 1121.2% | 瑞穗 | $34 → $69 | 升级 | 中性→购买 |
03/02/2021 | 696.43% | 摩根士丹利 | $50 → $45 | 维护 | 等重 |
02/17/2021 | 590.24% | 摩根大通 | $76 → $39 | 评级下调 | 超重→中性 |
11/11/2020 | 1032.7% | 贝伦伯格 | → $64 | 开始承保 | →购买 |
11/11/2020 | 784.92% | 摩根士丹利 | $68 → $50 | 维护 | 等重 |
11/05/2020 | 873.42% | 派珀·桑德勒 | $70 → $55 | 维护 | 中性 |
11/05/2020 | 1333.58% | B of A证券 | $100 → $81 | 维护 | 买 |
11/05/2020 | 1652.15% | SVB Leerink | $133 → $99 | 维护 | 跑赢大盘 |
11/05/2020 | 891.12% | 蒙特利尔银行资本 | → $56 | 评级下调 | 跑赢→市场表现 |
10/20/2020 | 2076.91% | 瑞穗 | → $123 | 开始承保 | →购买 |
08/10/2020 | 1103.5% | 摩根士丹利 | $73 → $68 | 维护 | 等重 |
08/06/2020 | 1811.44% | 蒙特利尔银行资本 | $112 → $108 | 维护 | 跑赢大盘 |
08/06/2020 | 1333.58% | 韦德布什 | $89 → $81 | 维护 | 跑赢大盘 |
07/13/2020 | 1669.85% | B of A证券 | $104 → $100 | 维护 | 买 |
06/12/2020 | 2253.9% | SVB Leerink | $129 → $133 | 维护 | 跑赢大盘 |
05/28/2020 | 1191.99% | 摩根士丹利 | $69 → $73 | 维护 | 等重 |
05/28/2020 | 2183.11% | SVB Leerink | $125 → $129 | 维护 | 跑赢大盘 |
05/13/2020 | 1669.85% | 加拿大皇家银行资本 | → $100 | 开始承保 | →跑赢大盘 |
05/12/2020 | 1882.23% | 蒙特利尔银行资本 | $107 → $112 | 维护 | 跑赢大盘 |
04/15/2020 | 1121.2% | 摩根士丹利 | $92 → $69 | 维护 | 等重 |
03/27/2020 | 1138.89% | Stifel | $94 → $70 | 升级 | 持有→购买 |
02/26/2020 | 1528.26% | 摩根士丹利 | $100 → $92 | 维护 | 等重 |
02/19/2020 | 1563.66% | Stifel | $96 → $94 | 维护 | 保持 |
02/03/2020 | 1669.85% | Evercore ISI集团 | $86 → $100 | 升级 | 线内→表现优异 |
12/13/2019 | 2289.3% | 奥本海默 | → $135 | 升级 | →表现强于大盘 |
12/09/2019 | 2731.76% | 富国银行 | $242 → $160 | 维护 | 超重 |
11/26/2019 | 2006.12% | SVB Leerink | → $119 | 升级 | 市场表现优于→ |
11/19/2019 | 1422.07% | Evercore ISI集团 | → $86 | 评级下调 | 胜过→同线 |
11/04/2019 | — | 韦德布什 | 升级 | 中性→表现优异 | |
11/01/2019 | 1404.37% | 派珀·桑德勒 | $120 → $85 | 维护 | 中性 |
11/01/2019 | 1669.85% | 摩根士丹利 | $104 → $100 | 维护 | 等重 |
10/11/2019 | 1740.64% | 摩根士丹利 | $136 → $104 | 维护 | 等重 |
10/01/2019 | 1829.14% | Stifel | → $109 | 开始承保 | →保留 |
08/12/2019 | — | 威廉·布莱尔 | 评级下调 | 跑赢→市场表现 | |
08/06/2019 | 2306.99% | 摩根士丹利 | $143 → $136 | 维护 | 等重 |
06/18/2019 | 2731.76% | Maxim集团 | → $160 | 升级 | 持有→购买 |
06/17/2019 | 2784.85% | 蒙特利尔银行资本 | $191 → $163 | 维护 | 跑赢大盘 |
05/15/2019 | 2218.5% | 韦德布什 | $166 → $131 | 评级下调 | 跑赢→中性 |
03/05/2019 | — | 利林克·斯旺 | 评级下调 | 跑赢→市场表现 | |
02/26/2019 | — | 考恩公司 | 开始承保 | →跑赢大盘 | |
01/23/2019 | 2749.46% | 卡纳科特·格纳奇 | $250 → $161 | 维护 | 买 |
12/20/2018 | — | 雷蒙德·詹姆斯 | 开始承保 | →强势购买 | |
12/19/2018 | 2112.31% | 摩根士丹利 | $185 → $125 | 维护 | 等重 |
12/06/2018 | 2023.82% | 派珀·桑德勒 | $240 → $120 | 评级下调 | 超重→中性 |
11/28/2018 | 2466.28% | 利林克·斯旺 | → $145 | 开始承保 | →跑赢大盘 |
11/05/2018 | 3174.22% | 摩根士丹利 | $186 → $185 | 维护 | 等重 |
11/05/2018 | 2837.95% | 韦德布什 | $204 → $166 | 维护 | 跑赢大盘 |
11/05/2018 | 2908.74% | 詹尼·蒙哥马利·斯科特 | $170 → $170 | 升级 | 中性→购买 |
10/15/2018 | 3191.92% | 摩根士丹利 | $190 → $186 | 维护 | 等重 |
06/19/2018 | 3970.65% | Evercore ISI集团 | $175 → $230 | 升级 | 线内→表现优异 |
05/31/2018 | 4147.64% | 派珀·桑德勒 | → $240 | 假设 | 超重→超重 |
05/03/2018 | 3722.87% | 蒙特利尔银行资本 | $222 → $216 | 维护 | 跑赢大盘 |
03/21/2018 | 3598.98% | 摩根士丹利 | $152 → $209 | 维护 | 等重 |
03/14/2018 | 3793.67% | 詹尼·蒙哥马利·斯科特 | → $220 | 开始承保 | →中性 |
03/05/2018 | 4183.03% | 威廉·布莱尔 | → $242 | 开始承保 | →跑赢大盘 |
02/26/2018 | 2590.17% | 摩根士丹利 | $151 → $152 | 维护 | 等重 |
02/22/2018 | 3758.27% | B of A证券 | $185 → $218 | 维护 | 中性 |
02/22/2018 | 3829.06% | 蒙特利尔银行资本 | $215 → $222 | 维护 | 跑赢大盘 |
01/25/2018 | — | 利林克·斯旺 | 评级下调 | 跑赢→市场表现 | |
12/21/2017 | — | 奥本海默 | 开始承保 | →性能 | |
12/13/2017 | — | Maxim集团 | 评级下调 | 购买→Hold | |
12/11/2017 | — | 杰富瑞 | 升级 | 持有→购买 | |
12/05/2017 | 3475.09% | 卡纳科特·格纳奇 | → $202 | 开始承保 | →购买 |
11/30/2017 | 3439.7% | Maxim集团 | $170 → $200 | 维护 | 买 |
11/06/2017 | — | Evercore ISI集团 | 评级下调 | 胜过→同线 | |
11/03/2017 | 2784.85% | SunTrust Robinson Humphrey | $108 → $163 | 维护 | 买 |
11/03/2017 | — | 摩根士丹利 | 升级 | 重量不足的→等重 | |
11/02/2017 | 2767.16% | 巴克莱 | $151 → $162 | 维护 | 超重 |
11/02/2017 | — | BTIG | 升级 | 中性→购买 | |
10/30/2017 | 2767.16% | 蒙特利尔银行资本 | $134 → $162 | 维护 | 跑赢大盘 |
10/16/2017 | — | Evercore ISI集团 | 升级 | 线内→表现优异 | |
10/11/2017 | — | 杰富瑞 | 评级下调 | 购买→Hold | |
10/02/2017 | — | 摩根士丹利 | 评级下调 | 等重→减码 | |
09/07/2017 | 2572.47% | 巴克莱 | → $151 | 开始承保 | →超重 |
08/17/2017 | 1705.25% | Evercore ISI集团 | → $102 | 开始承保 | →串联 |
08/07/2017 | 1758.34% | 摩根士丹利 | $103 → $105 | 维护 | 等重 |
bluebird bio Questions & Answers
青鸟传记问答
The latest price target for bluebird bio (NASDAQ: BLUE) was reported by Barclays on August 5, 2022. The analyst firm set a price target for $5.00 expecting BLUE to fall to within 12 months (a possible -11.51% downside). 19 analyst firms have reported ratings in the last year.
巴克莱银行于2022年8月5日报道了蓝鸟生物(纳斯达克:蓝色)的最新目标价。这家分析公司将目标价定为5美元,预计蓝色将在12个月内跌至(可能下跌11.51%)。去年有19家分析公司公布了评级。
The latest analyst rating for bluebird bio (NASDAQ: BLUE) was provided by Barclays, and bluebird bio upgraded their equal-weight rating.
蓝鸟生物(纳斯达克:蓝)的最新分析师评级由巴克莱提供,蓝鸟生物上调了其同等权重的评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of bluebird bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for bluebird bio was filed on August 5, 2022 so you should expect the next rating to be made available sometime around August 5, 2023.
分析师在进行了广泛的研究后得出了股票评级,其中包括查阅公共财务报表,与蓝鸟生物的高管和客户交谈,以及收听收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。蓝鸟生物的上一次评级是在2022年8月5日提交的,所以你应该预计下一次评级将在2023年8月5日左右的某个时候提供。
While ratings are subjective and will change, the latest bluebird bio (BLUE) rating was a upgraded with a price target of $3.00 to $5.00. The current price bluebird bio (BLUE) is trading at is $5.65, which is out of the analyst's predicted range.
虽然评级是主观的,并将发生变化,但最新的蓝鸟生物(蓝色)评级被上调,目标价从3.00美元到5.00美元。蓝鸟生物(Blue)目前的交易价格为5.65美元,超出了分析师的预测区间。
译文内容由第三方软件翻译。